Neumora 治疗学报告Q3 EPS失灵,是第三阶段主要抑郁症试验的主要产品。 Neumora Therapeutics reports Q3 EPS miss, lead product in Phase 3 trials for major depressive disorder.

Neumora理疗公司是一家临床阶段生物制药公司,报告Q3 EPS为(0.37美元)与估计数。 Neumora Therapeutics, a clinical-stage biopharmaceutical firm, reported a Q3 EPS of ($0.37) vs estimates. 九家经纪人向该公司提出了“机动购买”平均建议,协商一致的目标价格为22.33美元。 Nine brokers have given the company a "Moderate Buy" average recommendation, with a consensus target price of $22.33. 该公司的主导产品Navacaprant(Navacaprant(NMRA-140))正在第3阶段对重大抑郁症进行试验。 The firm's lead product, navacaprant (NMRA-140), is in Phase 3 trials for major depressive disorder. 机构投资者和对冲基金增加了在该公司的股份,拥有47.65%的所有权。 Institutional investors and hedge funds have been adding to their stakes in the company, with 47.65% ownership.